TY - JOUR
T1 - In vitro activity of the arylaminoartemisinin GC012 against Helicobacter pylori and its effects on biofilm
AU - Sisto, Francesca
AU - Carradori, Simone
AU - D’alessandro, Sarah
AU - Santo, Nadia
AU - Lattuada, Norma
AU - Haynes, Richard K.
AU - Taramelli, Donatella
AU - Grande, Rossella
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Includes bibliographical references
PY - 2022/7
Y1 - 2022/7
N2 - This study evaluated the in vitro activity of the arylaminoartemisinin GC012, readily obtained from dihydroartemisinin (DHA), against clinical strains of Helicobacter pylori (H. pylori) with different antibiotic susceptibilities in the planktonic and sessile state. The activity was assessed in terms of bacteriostatic and bactericidal potential. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined by the broth microdilution method. After treatment with GC012, all bacterial strains showed significantly lower MIC and MBC values compared to those of DHA. The effect of combination of GC012 with antibiotics was examined using the checkerboard method. GC012 displayed synergistic interactions with metronidazole, clarithromycin, and amoxicillin in all the strains. The antibiofilm activity was evaluated via crystal violet staining, AlamarBlue® assay, colony-forming unit count, and fluorescence microscopy. At 1/2 MIC and 1/4 MIC concentration, both GC012 and DHA inhibited biofilm formation, but only GC012 showed a minimal biofilm eradication concentration (MBEC) on mature biofilm. Furthermore, both compounds induced structural changes in the bacterial membrane, as observed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM). It is thereby demonstrated that GC012 has the potential to be efficacious against H. pylori infection.
AB - This study evaluated the in vitro activity of the arylaminoartemisinin GC012, readily obtained from dihydroartemisinin (DHA), against clinical strains of Helicobacter pylori (H. pylori) with different antibiotic susceptibilities in the planktonic and sessile state. The activity was assessed in terms of bacteriostatic and bactericidal potential. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined by the broth microdilution method. After treatment with GC012, all bacterial strains showed significantly lower MIC and MBC values compared to those of DHA. The effect of combination of GC012 with antibiotics was examined using the checkerboard method. GC012 displayed synergistic interactions with metronidazole, clarithromycin, and amoxicillin in all the strains. The antibiofilm activity was evaluated via crystal violet staining, AlamarBlue® assay, colony-forming unit count, and fluorescence microscopy. At 1/2 MIC and 1/4 MIC concentration, both GC012 and DHA inhibited biofilm formation, but only GC012 showed a minimal biofilm eradication concentration (MBEC) on mature biofilm. Furthermore, both compounds induced structural changes in the bacterial membrane, as observed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM). It is thereby demonstrated that GC012 has the potential to be efficacious against H. pylori infection.
KW - amino-artemisinin
KW - antibiotics
KW - biofilm
KW - dihydroartemisinin
KW - FICI
KW - Helicobacter pylori
KW - MBEC
KW - MBIC
KW - MIC
KW - synergism
UR - http://www.scopus.com/inward/record.url?scp=85133572817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133572817&partnerID=8YFLogxK
U2 - 10.3390/pathogens11070740
DO - 10.3390/pathogens11070740
M3 - Article
C2 - 35889986
AN - SCOPUS:85133572817
SN - 2076-0817
VL - 11
SP - 1
EP - 17
JO - Pathogens
JF - Pathogens
IS - 7
M1 - 740
ER -